Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leukemia Research 2022, 119: 106903. PMID: 35717689, PMCID: PMC11583043, DOI: 10.1016/j.leukres.2022.106903.Peer-Reviewed Original ResearchConceptsPolycythemia veraHigh-risk essential thrombocythemiaHigh-risk polycythemia veraLarge multi-centre databaseGuideline-directed managementUse of anagrelideMedian platelet countMulti-center cohortMulti-center databaseVon Willebrand diseaseANA therapyPrior thrombosisTolerability profileCytoreductive agentsMedian durationArterial thrombosesExtreme thrombocytosisPlatelet countTherapeutic endpointsSafety outcomesAnagrelideEssential thrombocythemiaClinical practicePatientsPlatelet control